We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00776841
First Posted: October 21, 2008
Last Update Posted: November 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Galmed Medical Reserch
  Purpose

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers.

Primary Objectives:

  1. To assess and characterize the safety and tolerability of Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
  2. To assess the pharmacokinetics of Aramchol at the administered doses

Condition Intervention Phase
Healthy Drug: Aramchol Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by Galmed Medical Reserch:

Primary Outcome Measures:
  • To assess safety and tolerability and Pharmacokinetics of Aramchol at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, subjects receiving multiple doses (Part B) [ Time Frame: day 1 to 6 ]

Secondary Outcome Measures:
  • To assess and characterize the drug effect on lipid profile and functional pharmacodynamics following single and multiple dose administrations. [ Time Frame: day 1 to 6 ]

Enrollment: 41
Study Start Date: September 2008
Study Completion Date: October 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo control single dose
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at dose 30 mg to 900 mg
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 1
Dose 30 mg
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at dose 30 mg to 900 mg
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 2
Dose 100 mg
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at dose 30 mg to 900 mg
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 3
Dose 300 mg
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at dose 30 mg to 900 mg
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 4
Dose 900 mg
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at dose 30 mg to 900 mg
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 1 repeated
Dose 30 mg for 4 days
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Experimental: Dose 2 repeated
Dose high for 4 days
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Other Names:
  • 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid)
  • fatty-acid bile-acid conjugate
Drug: Aramchol
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

Detailed Description:

Number of Subjects:

Total: A total of 46 healthy subjects will be enrolled. Part A: Sixteen (16) subjects will participate in four, 8-person dosing periods. Each cohort will be alternately dosed twice.

Part B: Thirty (30) subjects will be enrolled in two, 15-person dose-ascending cohorts.

Main Inclusion Criteria:

Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written informed consent Part B: Mildly overweight (25<BMI<33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides < 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written informed consent
  • Part B: Mildly overweight (25<BMI <33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides < 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent

Major Exclusion Criteria:

  • History of significant neurological (including history of seizures or EEG abnormalities), renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety, tension or agitation) or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications.
  • History of drug or alcohol abuse.
  • Known allergy to any drug. Known allergy to any drug.
  • Clinically significant abnormalities found in the screening physical exam.
  • Significant abnormalities in clinical laboratory parameters (hematology, biochemistry, urinalysis) determined within 40 days of the start of the study and on Day (-1) before first dosing session. Parameters to be measured are those shown in Appendix 2.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776841


Locations
Israel
Tasmc Clinical Research Center
Tel-Aviv, Israel, 64239
Sponsors and Collaborators
Galmed Medical Reserch
Investigators
Principal Investigator: Jacob Atsmon, M.D. TASMC CLINICAL RESEARCH CENTER
  More Information

Responsible Party: Dr. Itzchak Angel, Vice President, Research & Development, Galmed Medical Research
ClinicalTrials.gov Identifier: NCT00776841     History of Changes
Other Study ID Numbers: PROTOCOL No: TRC 037/10072
First Submitted: October 19, 2008
First Posted: October 21, 2008
Last Update Posted: November 3, 2010
Last Verified: November 2010

Keywords provided by Galmed Medical Reserch:
Phase-I
Hypercholesterolemia
Obesity
fatty liver
Part A: Healthy male volunteers Part B: Mildly overweight, otherwise healthy hypercholesterolemic male volunteers